Syndax Pharmaceuticals Inc
(NAS:SNDX)
$
13.07
-0.24 (-1.8%)
Market Cap: 1.12 Bil
Enterprise Value: 710.08 Mil
PE Ratio: 0
PB Ratio: 3.04
GF Score: 32/100 Syndax Pharmaceuticals Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
Sep 09, 2021 / 01:30PM GMT
Release Date Price:
$18.06
(+1.86%)
David Neil Lebowitz
Morgan Stanley, Research Division - VP
Good morning. Welcome again to the 19th Annual Morgan Stanley Healthcare conference. I'm one of the biotech analysts here. My name is David Lebowitz. Before we get started, let me read the requisite disclosures.
For important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative.
And with that, I'm going to begin. For the next session, I have from Syndax Pharmaceuticals, CEO, Briggs Morrison; President and COO, Michael Metzger; and CFO, Daphne Karydas.
Questions & Answers
David Neil Lebowitz;Briggs W. Morrison
Morgan Stanley, Research Division - VP;Syndax Pharmaceuticals, Inc. - CEO
I guess if we just start out, can you just give a top line description of Syndax, where you've been and where you're going?
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot